Keywords: novartis, rasilez, may, cut, heart, attack, severity

Novartis' Rasilez may cut heart attack severity

Article | 10 September 2007

Print This

Drug major Novartis says that its high blood pressure treatment Rasilez (aliskiren), which was co-developed with fellow Swiss firm Speedel ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in